Lila Levinson, PhD,  Science Writer—

One-year treatment with Trikafta — a widely used, approved medication for people with cystic fibrosis (CF) — significantly eases symptoms and improves outcomes, regardless of whether or not patients were previously treated with other CFTR modulators, a new real-world study reports. Among other benefits, Trikafta — a combination…

Northwestern University scientists developed a wearable patch that could help cystic fibrosis (CF) patients manage their disease from home. A study showed that the patch, developed in collaboration with scientists at Epicore Biosystems, measured sweat chloride in test participants as effectively as the gold standard method for sweat chloride assessment…

The Food and Drug Administration (FDA) placed the U.S. portion of a Phase 2b trial of BX004, a treatment for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF), on clinical hold because of questions about a third-party drug delivery device. The treatment’s developer, Biomx, believes the FDA’s…

Interim results from the first nine participants in a Phase 2 clinical trial testing Arcturus Therapeutics’ experimental inhaled therapy ARCT-032 in adults with cystic fibrosis (CF) are expected next month. The U.S.-based study, called LunairCF (NCT06747858), is still recruiting CF patients who aren’t eligible for CFTR…

A new noninvasive prenatal test for cystic fibrosis (CF) and three other inherited conditions, launched by Natera, uses a sample of the mother’s blood to screen fetal DNA. The test, called Fetal Focus, may be particularly useful when the baby’s biological father isn’t available for genetic testing to…

The first participant has been dosed in a Phase 2b clinical trial testing BiomX’s experimental inhaled therapy BX004 in adults with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa lung infection. “This first patient dosing marks a significant milestone for our BX004 program and for CF patients with chronic P.

Alyftrek has been approved by the European Commission to treat cystic fibrosis (CF) patients 6 years and older who have at least one non-class 1 mutation in the CFTR gene. This indication in the European Union (EU) represents the broadest label for Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) in the world, according to the…

Although infants with cystic fibrosis (CF) may have lung function abnormalities between the ages of 3 months and 2 years, these are predominantly mild and temporary, a real-world study reports. Tests that indicate abnormal lung function may influence decisions about clinical management of CF. Clinical findings, however, including evidence…

SION-719 and SION-451, two NBD1 stabilizers Sionna Therapeutics is developing to restore CFTR protein function in cystic fibrosis (CF), will advance to the next stages of clinical development after positive safety results in Phase 1 clinical trials. Sionna tested both compounds in healthy volunteers to assess safety and…